Table 2.
S. # | Year | Place | Method | Sample size | Seroprevalence (%) | Ref. |
1 | 2009 | Mirpurkhas | ELISA7 | 804 | 15.05 | [25] |
2 | 2010 | Multan | ELISA1 | 10000 | 4.90 | [88] |
3 | 2010 | Peshawar | ELISA7 | 32042 | 1.57 | [92] |
4 | 2011 | KPK/FATA | ELISA2 | 7148 | 1.89 | [89] |
5 | 2011 | KPK/FATA | ELISA2 | 62251 | 2.60 | [91] |
6 | 2011 | Karachi | -8 | 5717 | 1.90 | [86] |
7 | 2012 | Karachi | ELISA3 | 5517 | 2.00 | [83] |
8 | 2012 | Peshawar | ELISA2 | 127828 | 2.46 | [84] |
9 | 2012 | Sargodha | ELISA3 | 100 | 12.00 | [85] |
10 | 2013 | Karachi | MEIA/CLIA4 | 108598 | 2.61 | [87] |
11 | 2013 | Quetta | ELISA2 | 356 | 20.8 | [27] |
12 | 2013 | Lahore | ELISA5 | 245 | 15.00 | [82] |
13 | 2014 | Karachi | CLIA6 | 42830 | 1.65 | [90] |
Labkit Chemelex, Barcelona, Spain;
Biokit;
General Biologicals Corporation, Taiwan;
Abbott Diagnostics,
DiaSorin;
Ortho Clinical Diagnostics, NJ, United States;
Manufacturer not mentioned in cited reference;
Method not mentioned in cited reference. KPK: Khyber Pakhtunkhwa; FATA: Federally Administered Tribal Areas; ELISA: Enzyme linked immunosorbent assay; MEIA: Microparticle immunoassay; CLIA: Chemiluminescence immunoassay.